Merck & Co., Inc. (MRK)

US — Healthcare Sector
Peers: ABBV  PFE  LLY  BMY  AMGN  GILD  JNJ 

Automate Your Wheel Strategy on MRK

With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MRK
  • Rev/Share 25.2556
  • Book/Share 19.1229
  • PB 4.1519
  • Debt/Equity 0.7209
  • CurrentRatio 1.4103
  • ROIC 0.2167

 

  • MktCap 199099568700.0
  • FreeCF/Share 6.7321
  • PFCF 11.6849
  • PE 11.511
  • Debt/Assets 0.3027
  • DivYield 0.0404
  • ROE 0.3816

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade MRK Citigroup Buy Neutral -- $84 May 14, 2025
Initiation MRK Cantor Fitzgerald -- Neutral -- $85 April 22, 2025
Downgrade MRK Deutsche Bank Buy Hold $128 $105 Feb. 18, 2025
Downgrade MRK TD Cowen Buy Hold $121 $100 Feb. 10, 2025
Downgrade MRK Truist Buy Hold -- $110 Jan. 8, 2025
Downgrade MRK BMO Capital Markets Outperform Market Perform $136 $105 Dec. 20, 2024
Resumed MRK BofA Securities -- Buy -- $121 Dec. 10, 2024
Upgrade MRK HSBC Securities Hold Buy -- $130 Dec. 4, 2024
Initiation MRK Bernstein -- Market Perform -- $115 Oct. 17, 2024

News

Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
MRK, WMT
Published: February 11, 2025 by: 24/7 Wall Street
Sentiment: Positive

Media personality Jim Cramer often makes bold statements about companies and a lot of times, he proves himself correct.

Read More
image for news Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
Merck: 4 No-Brainer Reasons to Buy This Dip
MRK
Published: February 10, 2025 by: MarketBeat
Sentiment: Neutral

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts.

Read More
image for news Merck: 4 No-Brainer Reasons to Buy This Dip
Better High-Yield Dividend Stock: Pfizer vs. Merck
MRK, PFE
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.

Read More
image for news Better High-Yield Dividend Stock: Pfizer vs. Merck

About Merck & Co., Inc. (MRK)

  • IPO Date 1978-01-13
  • Website https://www.merck.com
  • Industry Drug Manufacturers - General
  • CEO Mr. Robert M. Davis J.D.
  • Employees 73000

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.